BIOMAT Database Logo BIOMAT Database Logo

The Trend of Urinary N Terminal Probrain Natriuretic Peptide in Extremely Low Birth Weight Infants during the Neonatal Period. 2022

Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida.

N-terminal probrain natriuretic peptide (NT-proBNP) is a biomarker of interest in many cardiopulmonary diseases in extremely low birth weight (ELBW) Infants. However, there is a gap in knowledge about the trend of ELBW infant's urinary NT-proBNP during the neonatal period. To determine the trend of urinary NT-proBNP during the first 4 weeks of life of an ELBW infant. We analyzed prospectively enrolled 87 ELBW infants. Urinary NT-proBNP to creatinine ratios were measured on days 1 to 7, 14, and 28 of life. We plotted each study point's means to determine the trend of urinary NT-proBNP over the entire neonatal period. Data were analyzed using the Friedman analysis of variance for comparative analysis of study points. Urinary NT-proBNP/creatinine ratios were significantly elevated on days 1 to 7 (mean 2,452, ± 1,518) than day 14 (mean 747, ± 176), and day 28 (mean 149, ± 54), p = 0.001. Overall, urinary NT-proBNP levels were highest during days 1 to 3 (mean 3,232, ± 1,255) and lowest on day 28 (mean 149, ± 54). Urinary NT-proBNP levels are higher during the first week in ELBW infants with a downward trend during the neonatal period, the lowest values at 4 weeks postnatal age. More studies are required to determine the clinical utility of this trend during and beyond the neonatal period. · NT-proBNP is a biomarker for monitoring cardiac disease in premature infants.. · The trend of urinary NT-proBNP is unknown in premature infants.. · A trend of urinary NT-proBNP was determined during the first 4 weeks in premature infants..

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007234 Infant, Premature A human infant born before 37 weeks of GESTATION. Neonatal Prematurity,Premature Infants,Preterm Infants,Infant, Preterm,Infants, Premature,Infants, Preterm,Premature Infant,Prematurity, Neonatal,Preterm Infant
D007235 Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D052577 Infant, Extremely Low Birth Weight An infant whose weight at birth is less than 1000 grams (2.2 lbs), regardless of GESTATIONAL AGE. Extremely Low Birth Weight Infant

Related Publications

Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Urinary Terminal Probrain Natriuretic Peptide in Preterm Infants.
May 2024, American journal of perinatology,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants.
February 2009, Journal of perinatology : official journal of the California Perinatal Association,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Urinary acidification in extremely low birth weight infants.
December 2002, Early human development,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Usefulness of measurement of urinary N-terminal pro-brain natriuretic peptide in neonatal period.
August 2011, Pediatrics international : official journal of the Japan Pediatric Society,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma.
February 2001, Scandinavian journal of clinical and laboratory investigation,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.
September 2007, Heart and vessels,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina.
October 2011, European journal of clinical investigation,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
N-terminal probrain natriuretic peptide in patients with acute coronary syndrome
.
January 2017, International journal of clinical pharmacology and therapeutics,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
N-terminal probrain natriuretic peptide as a biomarker of cardioembolic stroke.
October 2011, International journal of stroke : official journal of the International Stroke Society,
Safdar S Khan, and Henrietta S Bada, and Maritza Torres, and Melvin Almodovar, and Mina Hanna
N-terminal proBrain natriuretic peptide levels predict short-term poststroke survival.
January 2006, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association,
Copied contents to your clipboard!